# Chemomab Therapeutics Ltd.: financial statements, quarterly

CMMB · Nasdaq · CIK 1534248 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cmmb.md) · [Financials](/companies/cmmb/financials.md) · [Filings](/companies/cmmb/filings.md) · [Insiders](/companies/cmmb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cmmb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2020 (2020-06-30) | Q3 FY2020 (2020-09-30) | Q4 FY2020 (2020-12-31) | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q4 FY2021 (2021-12-31) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [847](/filings/0001178913-21-002696.md) | [1,031](/filings/0001178913-21-003509.md) | [1,254 d](/filings/0001178913-22-001304.md) | [1,157](/filings/0001178913-22-001919.md) | [1,307](/filings/0001178913-22-003074.md) | [1,487](/filings/0001178913-22-003931.md) | [2,383 d](/filings/0001178913-24-001124.md) | [2,745](/filings/0001178913-23-001807.md) | [2,914](/filings/0001178913-22-003074.md) | [5,423](/filings/0001178913-22-003931.md) | [5,895 d](/filings/0001178913-25-001205.md) | [6,887](/filings/0001178913-23-001807.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | [0.0](/filings/0001178913-22-003074.md) | [0.0](/filings/0001178913-22-003931.md) | [0.0 d](/filings/0001178913-24-001124.md) | [0.0](/filings/0001178913-23-001807.md) | [(544)](/filings/0001178913-22-003074.md) | [0.0](/filings/0001178913-22-003931.md) | [10.0 d](/filings/0001178913-25-001205.md) | [21.0](/filings/0001178913-23-001807.md) |
| Net income | $k | [(1,081)](/filings/0001178913-21-003509.md) | [(1,224)](/filings/0001178913-21-003509.md) | [(1,951) d](/filings/0001178913-22-001304.md) | [(1,704)](/filings/0001178913-22-003931.md) | [(2,770)](/filings/0001178913-22-003931.md) | [(2,968)](/filings/0001178913-22-003931.md) | [(5,036) d](/filings/0001178913-24-001124.md) | [(5,104)](/filings/0001178913-23-001807.md) | [(6,190)](/filings/0001178913-22-003931.md) | [(8,080)](/filings/0001178913-22-003931.md) | [(8,272) d](/filings/0001178913-25-001205.md) | [(8,753)](/filings/0001178913-23-001807.md) |
| Diluted EPS | $ per share | [0.01](/filings/0001178913-21-002696.md) | [0.01](/filings/0001178913-21-003509.md) | not reported | [0.01](/filings/0001178913-22-001919.md) | [0.01](/filings/0001178913-22-003074.md) | [0.01](/filings/0001178913-22-003931.md) | not reported | [0.02](/filings/0001178913-23-001807.md) | [0.03](/filings/0001178913-22-003074.md) | [0.04](/filings/0001178913-22-003931.md) | not reported | [0.04](/filings/0001178913-23-001807.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | [0.01](/filings/0001178913-22-003074.md) | [0.01](/filings/0001178913-22-003931.md) | not reported | [0.02](/filings/0001178913-23-001807.md) | [0.03](/filings/0001178913-22-003074.md) | [0.04](/filings/0001178913-22-003931.md) | not reported | [0.04](/filings/0001178913-23-001807.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted, us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | FY2021 (2021-12-31) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [58.2](/filings/0001104659-21-065588.md) | [45.4](/filings/0001178913-21-002696.md) | [37.7](/filings/0001178913-21-003509.md) | [15.2](/filings/0001178913-23-001041.md) | [13.8](/filings/0001178913-22-001919.md) | [9.9](/filings/0001178913-22-003074.md) | [10.7](/filings/0001178913-22-003931.md) | [13.5](/filings/0001178913-24-001124.md) | [20.8](/filings/0001178913-23-001807.md) | [9.3](/filings/0001178913-25-001205.md) | [6.1](/filings/0001178913-26-001593.md) | [7.6](/filings/0001178913-26-001593.md) |
| Current assets | $m | [59.5](/filings/0001104659-21-065588.md) | [68.8](/filings/0001178913-21-002696.md) | [65.8](/filings/0001178913-21-003509.md) | [62.7](/filings/0001178913-23-001041.md) | [59.3](/filings/0001178913-22-001919.md) | [54.8](/filings/0001178913-22-003074.md) | [48.7](/filings/0001178913-22-003931.md) | [41.7](/filings/0001178913-24-001124.md) | [33.8](/filings/0001178913-23-001807.md) | [20.9](/filings/0001178913-25-001205.md) | [16.0](/filings/0001178913-26-001593.md) | [13.4](/filings/0001178913-26-001593.md) |
| Total assets | $m | [60.1](/filings/0001104659-21-065588.md) | [70.5](/filings/0001178913-21-002696.md) | [67.4](/filings/0001178913-21-003509.md) | [64.4](/filings/0001178913-23-001041.md) | [61.0](/filings/0001178913-22-001919.md) | [56.4](/filings/0001178913-22-003074.md) | [50.2](/filings/0001178913-22-003931.md) | [43.1](/filings/0001178913-24-001124.md) | [35.0](/filings/0001178913-23-001807.md) | [22.2](/filings/0001178913-25-001205.md) | [17.0](/filings/0001178913-26-001593.md) | [13.8](/filings/0001178913-26-001593.md) |
| Current liabilities | $m | [4.6](/filings/0001104659-21-065588.md) | [2.2](/filings/0001178913-21-002696.md) | [1.6](/filings/0001178913-21-003509.md) | [2.7](/filings/0001178913-23-001041.md) | [3.5](/filings/0001178913-22-001919.md) | [4.4](/filings/0001178913-22-003074.md) | [5.5](/filings/0001178913-22-003931.md) | [6.7](/filings/0001178913-24-001124.md) | [7.0](/filings/0001178913-23-001807.md) | [4.8](/filings/0001178913-25-001205.md) | [3.2](/filings/0001178913-26-001593.md) | [1.5](/filings/0001178913-26-001593.md) |
| Total liabilities | $m | [5.0](/filings/0001104659-21-065588.md) | [2.5](/filings/0001178913-21-002696.md) | [1.9](/filings/0001178913-21-003509.md) | [2.9](/filings/0001178913-23-001041.md) | [3.7](/filings/0001178913-22-001919.md) | [4.5](/filings/0001178913-22-003074.md) | [5.6](/filings/0001178913-22-003931.md) | [6.8](/filings/0001178913-24-001124.md) | [7.1](/filings/0001178913-23-001807.md) | [5.2](/filings/0001178913-25-001205.md) | [3.4](/filings/0001178913-26-001593.md) | [1.5](/filings/0001178913-26-001593.md) |
| Shareholders' equity | $m | [55.2](/filings/0001178913-22-003931.md) | [68.0](/filings/0001178913-22-003931.md) | [65.5](/filings/0001178913-22-003931.md) | [61.5](/filings/0001178913-25-001205.md) | [57.2](/filings/0001178913-23-001807.md) | [51.8](/filings/0001178913-22-003931.md) | [44.6](/filings/0001178913-22-003931.md) | [36.2](/filings/0001178913-26-001593.md) | [28.0](/filings/0001178913-23-001807.md) | [17.0](/filings/0001178913-26-001593.md) | [13.5](/filings/0001178913-26-001593.md) | [12.3](/filings/0001178913-26-001593.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2020 (2020-06-30) | Q3 FY2020 (2020-09-30) | Q4 FY2020 (2020-12-31) | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q4 FY2021 (2021-12-31) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(873) d](/filings/0001178913-21-002696.md) | [(901) d](/filings/0001178913-21-003509.md) | [(1,555) d](/filings/0001178913-22-001304.md) | [(1,293)](/filings/0001178913-22-001919.md) | [(5,607) d](/filings/0001178913-22-003074.md) | [(2,580) d](/filings/0001178913-22-003931.md) | [(2,894) d](/filings/0001178913-24-001124.md) | [(3,711)](/filings/0001178913-23-001807.md) | [(5,701) d](/filings/0001178913-22-003074.md) | [(5,255) d](/filings/0001178913-22-003931.md) | [(5,703) d](/filings/0001178913-25-001205.md) | [(7,186)](/filings/0001178913-23-001807.md) |
| Capital expenditure | $k | [7.0 d](/filings/0001178913-21-002696.md) | [20.0 d](/filings/0001178913-21-003509.md) | [1.0 d](/filings/0001178913-22-001304.md) | [3.0](/filings/0001178913-22-001919.md) | [102 d](/filings/0001178913-22-003074.md) | [0.0 d](/filings/0001178913-22-003931.md) | [134 d](/filings/0001178913-24-001124.md) | [14.0](/filings/0001178913-23-001807.md) | [11.0 d](/filings/0001178913-22-003074.md) | [42.0 d](/filings/0001178913-22-003931.md) | [1.0 d](/filings/0001178913-25-001205.md) | [1.0](/filings/0001178913-23-001807.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [216](/filings/0001178913-22-003074.md) | [228](/filings/0001178913-22-003931.md) | [228](/filings/0001178913-23-001807.md) | [228](/filings/0001178913-22-003074.md) | [229](/filings/0001178913-22-003931.md) | [221](/filings/0001178913-23-001807.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 575,381,320 at 2025-12-31, from the cover of the [20-F filed 2026-03-23](/filings/0001178913-26-001593.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.